Amyris, Inc. (AMRS)

Market Cap	577.95M
Revenue (ttm)	258.82M
Net Income (ttm)	-341.15M
Shares Out	363.49M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,110
Open	1.55
Previous Close	1.53
Day's Range	1.52 - 1.59
52-Week Range	1.25 - 5.31
Beta	1.04
Analysts	Buy
Price Target	7.16 (+350.31%)
Earnings Date	Mar 7, 2023

About AMRS

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company ...

• Industry: Specialty Chemicals
• Sector: Materials
• IPO Date: Sep 28, 2010
• Employees: 980
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRS

Financial Performance

In 2021, Amyris's revenue was $341.82 million, an increase of 97.43% compared to the previous year's $173.14 million. Losses were -$270.46 million, -29.26% less than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for AMRS stock is "Buy." The 12-month stock price forecast is $7.16, which is an increase of 350.31% from the latest price.

Price Target

$7.16

(350.31% upside)

Analyst Consensus: Buy